Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19018903 | 0.88 | MAPT (0.44) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL16683542 | 0.88 | MAPT (0.44) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL3099567 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL3099571 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL13149938 | 0.87 | MEN1 (0.45) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL30747466 | 0.87 | MEN1 (0.40) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL6736374 | 0.86 | MAPT (0.50) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL1298246 | 0.86 | MAPT (0.50) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| SCHEMBL24593361 | 0.85 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL16763418 | 0.85 | MEN1 (0.44) | MEN1KMT2AMAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299386-A1 | Novel imidazole derivatives having protein kinase inhibitory activity and uses thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2024-09-12 | — | — | US | disclosed |
| WO-2023022463-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON PROTEIN PHOSPHORELATION AND USE THEREOF | 한양대학교 에리카산학협력단 | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299386-A1 | Novel imidazole derivatives having protein kinase inhibitory activity and uses thereof | MAPKAPK3, MAPK3, MAP2K3 | MEN1 3906/4885KMT2A 2612/4885MAPT 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.